Amyotrophic Lateral Sclerosis – Page 3 – CALIFORNIA NEUROLOGY SOCIETY

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

Sponsor:Mayo ClinicBrief Summary: ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through…

An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults With Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation

Sponsor:BiogenBrief Summary: The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB067 in participants…

A Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ANX005 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Sponsor:Annexon, Inc.Brief Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Intravenous ANX005…

A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS

Sponsor:Brainstorm-Cell TherapeuticsBrief Summary: This study will evaluate the safety and efficacy of repeated administration of NurOwn® (MSC-NTF cells) therapy, which…

An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) (VALOR (Part C))

Sponsor: Biogen Collaborator: Ionis Pharmaceuticals, Inc. Information provided by (Responsible Party): Biogen Brief Summary: The primary objective of Parts A…